Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atezolizumab + bevacizumab + beta-alanine
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy consists of the immune checkpoint inhibitor atezolizumab, the anti-angiogenic monoclonal antibody bevacizumab, and the amino acid supplement beta-alanine. It is being investigated by Peking Union Medical College Hospital as a first-line treatment for advanced hepatocellular carcinoma (HCC). Atezolizumab targets programmed death-ligand 1 (PD-L1) to restore anti-tumor T-cell activity, while bevacizumab inhibits vascular endothelial growth factor (VEGF) to suppress tumor angiogenesis and potentially enhance immune cell infiltration. Beta-alanine is added as a metabolic and nutritional adjunct to potentially improve physical performance and metabolic regulation in patients undergoing standard-of-care immunotherapy.
- Other names
- Atezolizumab combined with bevacizumab combined with β-alanineAtezolizumab + Bevacizumab + β-alanineAtezolizumab + Bevacizumab + beta-alanine
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on atezolizumab + bevacizumab + beta-alanine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atezolizumab + bevacizumab + beta-alanine.